Who
Gary Patou
Director
Company insider
Files Form 4 as: Director, Xenon Pharmaceuticals; Chief Medical Officer, Pacira BioSciences; Director, Oscient Pharmaceuticals.
In numbers
- Trades disclosed
- 148
- Buys
- 2
- Sells
- 30
- Bought
- $36K
- Sold
- $12.2M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 3 Jan 2006
- Last trade
- 5 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 8 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $70K1,322 at $53.14 | filing |
| 5 Jun 2026filed 8 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $70K1,322 at $53.14 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,507 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,507 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,593 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,593 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,645 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,645 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,645 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,645 | filing |
| 5 Jun 2025filed 6 Jun 2025 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,012 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,645 at $0.00 | filing |
| 22 Nov 2024filed 22 Nov 2024 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,500 at $0.00 | filing |
| 22 Nov 2024filed 22 Nov 2024 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,086 at $0.00 | filing |
| 22 Nov 2024filed 22 Nov 2024 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $26K3,500 at $7.38 | filing |
| 22 Nov 2024filed 22 Nov 2024 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $26K649 at $39.80 | filing |
| 22 Nov 2024filed 22 Nov 2024 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $117K2,851 at $41.11 | filing |
| 22 Nov 2024filed 22 Nov 2024 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $42K3,086 at $13.48 | filing |
| 22 Nov 2024filed 22 Nov 2024 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $42K1,046 at $39.80 | filing |
| 22 Nov 2024filed 22 Nov 2024 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $84K2,040 at $41.05 | filing |
News
Contrasting Xenon Pharmaceuticals (NASDAQ:XENE) and United Therapeutics (NASDAQ:UTHR)XENE · dailypolitical.com · 18 Oct 2026Head to Head Survey: Xenon Pharmaceuticals (NASDAQ:XENE) vs. United Therapeutics (NASDAQ:UTHR)XENE · themarketsdaily.com · 12 Oct 2026Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock Has Average Target Price of $70.27XENE · dailypolitical.com · 6 Oct 2026
0 headlines in the last 90 days name Gary Patou; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.